Emerging therapies for Parkinson's disease: From bench to bedside

Pharmacology and Therapeutics

Volumn 144, Issue 2, 2014, Pages 123-133

  Tarazi, F I ^a   Sahli, Z T ^a,c   Wolny, M ^b   Mousa, S A ^b  

^a MCLEAN HOSPITAL   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Adenosine A2A antagonists; Anti apoptotic agents; Deep brain stimulation; Pallidotomy; Stem cells; Viral vector gene therapy

Indexed keywords

ACETYLCYSTEINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIOXIDANT; CARBIDOPA PLUS LEVODOPA; GLIAL DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; MICRORNA; MONOAMINE OXIDASE INHIBITOR; NEUROTROPHIC FACTOR; NORPHENAZONE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UBIDECARENONE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; APOPTOSIS REGULATORY PROTEIN; DDIT4 PROTEIN, HUMAN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; TRANSCRIPTION FACTOR;

ARTICLE; BRAIN DEPTH STIMULATION; GAMMA KNIFE RADIOSURGERY; GENE; HUMAN; PALLIDOTOMY; PARKINSON DISEASE; PHARMACEUTICAL CARE; RTP801 GENE; STEM CELL TRANSPLANTATION; THALAMOTOMY; VIRAL GENE THERAPY; ANTAGONISTS AND INHIBITORS; GENE THERAPY; PROCEDURES; RADIOSURGERY;

ADENOSINE A2 RECEPTOR ANTAGONISTS; APOPTOSIS REGULATORY PROTEINS; DEEP BRAIN STIMULATION; GENETIC THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MAP KINASE KINASE KINASES; PALLIDOTOMY; PARKINSON DISEASE; RADIOSURGERY; STEM CELL TRANSPLANTATION; TRANSCRIPTION FACTORS; TRANSGLUTAMINASES;

EID: 84907890390     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.05.010     Document Type: Review

References (215)

1. G. Abbruzzese, P. Barone, U. Bonuccelli, L. Lopiano, and A. Antonini Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: Efficacy, safety and patient selection Funct Neurol 27 3 2012 147 154
2. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci 12 10 1989 366 375
3. G. Andringa, K.Y. Lam, M. Chegary, X. Wang, T.N. Chase, and M.C. Bennett Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease FASEB J 18 7 2004 932 934
4. A. Antonini, I.U. Isaias, M. Canesi, M. Zibetti, F. Mancini, and L. Manfredi Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome Mov Disord 22 8 2007 1145 1149
5. A. Antonini, and P. Odin Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease Parkinsonism Relat Disord 15 Suppl. 4 2009 S97 S100
6. N. Bajaj, R.A. Hauser, and I.D. Grachev Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes J Neurol Neurosurg Psychiatry 84 11 2013 1288 1295
7. R.J. Baldessarini, and F.I. Tarazi Brain dopamine receptors: A primer on their current status, basic and clinical Harv Rev Psychiatry 3 6 1996 301 325
8. X.Q. Bao, X.C. Kong, C. Qian, and D. Zhang FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in parkinson's disease models Neuroscience 202 2012 396 404
9. W. Bara-Jimenez, A. Sherzai, T. Dimitrova, A. Favit, F. Bibbiani, and M. Gillespie Adenosine A(2A) receptor antagonist treatment of Parkinson's disease Neurology 61 3 2003 293 296
10. R.T. Bartus, T.L. Baumann, L. Brown, B.R. Kruegel, J.M. Ostrove, and C.D. Herzog Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: Developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease Neurobiol Aging 34 1 2013 35 61
11. L.M. Bekris, I.F. Mata, and C.P. Zabetian The genetics of Parkinson disease J Geriatr Psychiatry Neurol 23 4 2010 228 242
12. T.S. Benamer, J. Patterson, D.G. Grosset, J. Booij, K. de Bruin, and E. van Royen Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group Mov Disord 15 3 2000 503 510
13. D. Berg, J. Godau, C. Trenkwalder, K. Eggert, I. Csoti, and A. Storch AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials Mov Disord 26 7 2011 1243 1250
14. A. Bjorklund, S.B. Dunnett, P. Brundin, A.J. Stoessl, C.R. Freed, and R.E. Breeze Neural transplantation for the treatment of Parkinson's disease Lancet Neurol 2 7 2003 437 445
15. P.J. Blanchet, S. Konitsiotis, and T.N. Chase Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys Mov Disord 13 5 1998 798 802
16. D. Bleakman, B.A. Ballyk, D.D. Schoepp, A.J. Palmer, C.P. Bath, and E.F. Sharpe Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles Neuropharmacology 35 12 1996 1689 1702
17. V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, and E. Krieger Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science 299 5604 2003 256 259
18. R. Borgohain, J. Szasz, P. Stanzione, C. Meshram, M. Bhatt, and D. Chirilineau for the Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations Mov Disord 29 2 2014 229 237
19. P. Brundin, R.E. Strecker, O. Lindvall, O. Isacson, O.G. Nilsson, and G. Barbin Intracerebral grafting of dopamine neurons. experimental basis for clinical trials in patients with Parkinson's disease Ann N Y Acad Sci 495 1987 473 496
20. K.J. Bulluss, E.A. Pereira, C. Joint, and T.Z. Aziz Pallidotomy after chronic deep brain stimulation Neurosurg Focus 35 5 2013 E5
21. D. Caccamo, M. Curro, and R. Ientile Potential of transglutaminase 2 as a therapeutic target Expert Opin Ther Targets 14 9 2010 989 1003
22. F. Calon, A.H. Rajput, O. Hornykiewicz, P.J. Bedard, and T. Di Paolo Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol Dis 14 3 2003 404 416
23. A. Case, and R.L. Stein Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor Biochemistry 46 4 2007 1106 1115
24. T.N. Chase, J.D. Oh, and P.J. Blanchet Neostriatal mechanisms in Parkinson's disease Neurology 51 2 Suppl. 2 1998 S30 S35
25. K.R. Chaudhuri, D.G. Healy, and A.H. Schapira National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: Diagnosis and management Lancet Neurol 5 3 2006 235 245
26. J.J. Chen Pharmacologic safety concerns in Parkinson's disease: facts and insights Int J Neurosci 121 Suppl. 2 2011 45 52
27. M. Cies̈lak, M. Komoszyński, and A. Wojtczak Adenosine A(2A) receptors in Parkinson's disease treatment Purinergic Signal 4 4 2008 305 312
28. E. Coley, R. Farhadi, S. Lewis, and I.R. Whittle The incidence of seizures following deep brain stimulating electrode implantation for movement disorders, pain and psychiatric conditions Br J Neurosurg 23 2 2009 179 183
29. C. Colosimo, and M. De Michele Motor fluctuations in Parkinson's disease: Pathophysiology and treatment Eur J Neurol 6 1 1999 1 21
30. M.R. Cookson, and O. Bandmann Parkinson's disease: Insights from pathways Hum Mol Genet 19 R1 2010 R21 R27
31. J. Cummings, S. Isaacson, R. Mills, H. Williams, K. Chi-Burris, and A. Corbett Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial Lancet 383 9916 2014 533 540
32. D.L. Cutler, A. Tendolkar, and I.D. Grachev Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects J Clin Pharm Ther 37 5 2012 578 587
33. E. Davis, F. Caiment, X. Tordoir, J. Cavaillé, A. Ferguson-Smith, and N. Cockett RNAi-mediated allelic trans-interaction at the imprinted Rtl1/Peg11 locus Curr Biol 15 8 2005 743 749
34. R. de la Fuente-Fernandez Role of DaTSCAN and clinical diagnosis in parkinson disease Neurology 78 10 2012 696 701
35. D. Devos, and French DUODOPA Study Group Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease Mov Disord 24 7 2009 993 1000
36. M.P. DeYoung, P. Horak, A. Sofer, D. Sgroi, and L.W. Ellisen Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling Genes Dev 22 2 2008 239 251
37. D.A. Di Monte, M. Lavasani, and A.B. Manning-Bog Environmental factors in Parkinson's disease Neurotoxicology 23 4-5 2002 487 502
38. J.G. Doench, and P.A. Sharp Specificity of microRNA target selection in translational repression Genes Dev 18 5 2004 504 511
39. B. Du, P. Wu, D.M. Boldt-Houle, and E.F. Terwilliger Efficient transduction of human neurons with an adeno-associated virus vector Gene Ther 3 3 1996 254 261
40. H. Dudek, S.R. Datta, T.F. Franke, M.J. Birnbaum, R. Yao, and G.M. Cooper Regulation of neuronal survival by the serine-threonine protein kinase akt Science 275 5300 1997 661 665
41. R. Dungo, and E.D. Deeks Istradefylline: First global approval Drugs 73 8 2013 875 882
42. M.J. During, M.G. Kaplitt, M.B. Stern, and D. Eidelberg Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation Hum Gene Ther 12 12 2001 1589 1591
43. K. Eggert, D. Squillacote, P. Barone, R. Dodel, R. Katzenschlager, and M. Emre German Competence Network on Parkinson's Disease. Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study Mov Disord 25 7 2010 896 905
44. W.J. Elias, D. Huss, T. Voss, J. Loomba, M. Khaled, and E. Zadicario A pilot study of focused ultrasound thalamotomy for essential tremor N Engl J Med 369 7 2013 640 648
45. L.W. Ellisen, K.D. Ramsayer, C.M. Johannessen, A. Yang, H. Beppu, and K. Minda REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species Mol Cell 10 5 2002 995 1005
46. J.D. Elsworth, and R.H. Roth Dopamine synthesis, uptake, metabolism, and receptors: Relevance to gene therapy of Parkinson's disease Exp Neurol 144 1 1997 4 9
47. R.G. Fariello Safinamide Neurotherapeutics 4 1 2007 110 116
48. E. Favre, B. Ballanger, S. Thobois, E. Broussolle, and P. Boulinguez Deep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson's disease Neurotherapeutics 10 1 2013 154 167
49. A. Feigin Nondopaminergic symptomatic therapies for Parkinson's disease: Turn on or turn off? Neurology 61 3 2003 286 287
50. A.J. Fenoy, and R.K. Simpson Jr. Management of device-related wound complications in deep brain stimulation surgery J Neurosurg 116 6 2012 1324 1332
51. H.H. Fernandez, and P. Odin Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease Curr Med Res Opin 27 5 2011 907 919
52. J. Fine, J. Duff, R. Chen, B. Chir, W. Hutchison, and A.M. Lozano Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease N Engl J Med 342 23 2000 1708 1714
53. W.J. Freed A perspective on transplantation therapy and stem cells for Parkinson's disease Cell Transplant 13 3 2004 319 327
54. C.R. Freed, P.E. Greene, R.E. Breeze, W.Y. Tsai, W. DuMouchel, and R. Kao Transplantation of embryonic dopamine neurons for severe Parkinson's disease N Engl J Med 344 10 2001 710 719
55. C.R. Freed, M.A. Leehey, M. Zawada, K. Bjugstad, L. Thompson, and R.E. Breeze Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol 250 Suppl. 3 2003 III44 III46
56. M. Fukuda, S. Kameyama, M. Yoshino, R. Tanaka, and H. Narabayashi Neuropsychological outcome following pallidotomy and thalamotomy for Parkinson's disease Stereotact Funct Neurosurg 74 1 2000 11 20
57. M. Geraerts, O. Krylyshkina, Z. Debyser, and V. Baekelandt Concise review: Therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis Stem Cells 25 2 2007 263 270
58. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, and M. Bunnage Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat Med 9 5 2003 589 595
59. J.G. Goldman, C.L. Vaughan, and C.G. Goetz An update expert opinion on management and research strategies in Parkinson's disease psychosis Expert Opin Pharmacother 12 13 2011 2009 2024
60. L. Grégoire, V.A. Jourdain, M. Townsend, A. Roach, and T. Di Paolo Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys Parkinsonism Relat Disord 19 5 2013 508 514
61. R. Grondin, Z. Zhang, A. Yi, W.A. Cass, N. Maswood, and A.H. Andersen Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys Brain 125 Pt 10 2002 2191 2201
62. M. Hadjivassiliou, P. Aeschlimann, A. Strigun, D.S. Sanders, N. Woodroofe, and D. Aeschlimann Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase Ann Neurol 64 3 2008 332 343
63. M. Hallett, and I. Litvan Evaluation of surgery for Parkinson's disease: A report of the therapeutics and technology assessment subcommittee of the american academy of neurology. the task force on surgery for Parkinson's disease Neurology 53 9 1999 1910 1921
64. M. Hallett, and I. Litvan Scientific position paper of the movement disorder society evaluation of surgery for Parkinson's disease. Task Force on Surgery for Parkinson's Disease of the American Academy Of Neurology Therapeutic and Technology Assessment Committee Mov Disord 15 3 2000 436 438
65. J. Hardy, H. Cai, M.R. Cookson, K. Gwinn-Hardy, and A. Singleton Genetics of Parkinson's disease and parkinsonism Ann Neurol 60 4 2006 389 398
66. M.I. Hariz, and A.T. Bergenheim A 10-year follow-up review of patients who underwent leksell's posteroventral pallidotomy for Parkinson disease J Neurosurg 94 4 2001 552 558
67. M.M. Harraz, T.M. Dawson, and V.L. Dawson MicroRNAs in Parkinson's disease J Chem Neuroanat 42 2 2011 127 130
68. A. Hartmann, S. Hunot, P.P. Michel, M.P. Muriel, S. Vyas, and B.A. Faucheux Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease Proc Natl Acad Sci U S A 97 6 2000 2875 2880
69. R.A. Hauser, M. Cantillon, E. Pourcher, F. Micheli, V. Mok, and M. Onofrj Preladenant in patients with Parkinson's disease and motor fluctuations: A phase 2, double-blind, randomised trial Lancet Neurol 10 3 2011 221 229
70. D.N. Hauser, and T.G. Hastings Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism Neurobiol Dis 51 2013 35 42
71. R.A. Hauser, J.P. Hubble, and D.D. Truong Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD Neurology 61 3 2003 297 303
72. N. Hermanowicz Management of Parkinson's disease. strategies, pitfalls, and future directions Postgrad Med 110 6 2001 15 18 (21-3, 28)
73. E.C. Hirsch, S. Hunot, B. Faucheux, Y. Agid, Y. Mizuno, and H. Mochizuki Dopaminergic neurons degenerate by apoptosis in Parkinson's disease Mov Disord 14 2 1999 383 385
74. M.J. Holmay, M. Terpstra, L.D. Coles, U. Mishra, M. Ahlskog, and G. Öz N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases Clin Neuropharmacol 36 4 2013 103 106
75. O. Hornykiewicz l-DOPA: From a biologically inactive amino acid to a successful therapeutic agent Amino Acids 23 1-3 2002 65 70
76. K. Hugdahl, K. Wester, and A. Asbjornsen The role of the left and right thalamus in language asymmetry: Dichotic listening in Parkinson patients undergoing stereotactic thalamotomy Brain Lang 39 1 1990 1 13
77. D.Y. Hwang, P. Ardayfio, U.J. Kang, E.V. Semina, and K.S. Kim Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice Brain Res Mol Brain Res 114 2 2003 123 131
78. D. Isacson, K. Bingefors, I.S. Kristiansen, and D. Nyholm Fluctuating functions related to quality of life in advanced Parkinson disease: Effects of duodenal levodopa infusion Acta Neurol Scand 118 6 2008 379 386
79. A. Jahangirvand, and A. Rajput Early use of amantadine to prevent or delay onset of levodopainduced dyskinesia in Parkinson's disease Mov Disord 28 Suppl. 1 2013 S207
80. J. Jankovic Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations Mov Disord 20 Suppl. 11 2005 S11 S16
81. J. Jankovic Parkinson's disease: Clinical features and diagnosis J Neurol Neurosurg Psychiatry 79 4 2008 368 376
82. T.M. Jeitner, E.J. Delikatny, J. Ahlqvist, H. Capper, and A.J. Cooper Mechanism for the inhibition of transglutaminase 2 by cystamine Biochem Pharmacol 69 6 2005 961 970
83. T.M. Jeitner, J.T. Pinto, B.F. Krasnikov, M. Horswill, and A.J. Cooper Transglutaminases and neurodegeneration J Neurochem 109 Suppl. 1 2009 160 166
84. P. Jenner Oxidative stress in Parkinson's disease Ann Neurol 53 Suppl. 3 2003 S26 S38
85. P. Jenner, and C.W. Olanow The pathogenesis of cell death in Parkinson's disease Neurology 66 10 Suppl. 4 2006 S24 S36
86. E.R. Kandel, J.H. Schwartz, and T.M. Jessell Neurotransmitters Principles of Neural Science 4th ed. 2000, July McGraw-Hill Medical 280 297
87. M.G. Kaplitt, A. Feigin, C. Tang, H.L. Fitzsimons, P. Mattis, and P.A. Lawlor Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial Lancet 369 9579 2007 2097 2105
88. J. Kim, K. Inoue, J. Ishii, W.B. Vanti, S.V. Voronov, and E. Murchison A microRNA feedback circuit in midbrain dopamine neurons Science 317 5842 2007 1220 1224
89. Y. Kim, Y.W. Park, Y.S. Lee, and D. Jeoung Hyaluronic acid induces transglutaminase II to enhance cell motility; role of Rac1 and FAK in the induction of transglutaminase II Biotechnol Lett 30 1 2008 31 39
90. T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, and S. Minoshima Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 6676 1998 605 608
91. D. Kondziolka, L.D. Lunsford, T.C. Witt, and J.C. Flickinger The future of radiosurgery: Radiobiology, technology, and applications Surg Neurol 54 6 2000 406 414
92. S. Konitsiotis, P.J. Blanchet, L. Verhagen, E. Lamers, and T.N. Chase AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys Neurology 54 8 2000 1589 1595
93. A. Kooshkabadi, L.D. Lunsford, D. Tonetti, J.C. Flickinger, and D. Kondziolka Gamma knife thalamotomy for tremor in the magnetic resonance imaging era J Neurosurg 118 4 2013 713 718
94. J.H. Kordower, M.E. Emborg, J. Bloch, S.Y. Ma, Y. Chu, and L. Leventhal Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease Science 290 5492 2000 767 773
95. J.M. Kyriakis, P. Banerjee, E. Nikolakaki, T. Dal, E.A. Rubie, and M.F. Ahmad The stress-activated protein kinase subfamily of c-Jun kinases Nature 369 1994 156 160
96. A.E. Lang, S. Gill, N.K. Patel, A. Lozano, J.G. Nutt, and R. Penn Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in parkinson disease Ann Neurol 59 3 2006 459 466
97. P.A. Lapchak A critical assessment of edaravone acute ischemic stroke efficacy trials: Is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 11 10 2010 1753 1763
98. K.H. Lee, S.Y. Chang, D.W. Roberts, and U. Kim Neurotransmitter release from high-frequency stimulation of the subthalamic nucleus J Neurosurg 101 3 2004 511 517
99. K.H. Lee, F.L. Hitti, S.Y. Chang, D.C. Lee, D.W. Roberts, and C.C. McIntyre High frequency stimulation abolishes thalamic network oscillations: An electrophysiological and computational analysis J Neural Eng 8 4 2011 046001
100. A. Lees, S. Fahn, K.M. Eggert, J. Jankovic, A. Lang, and F. Micheli Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease Mov Disord 27 2 2012 284 288
101. L. Leksell A stereotaxic apparatus for intracerebral surgery Acta Chir Scand 99 229 1949 33
102. B. Li, D. Yu, and Z. Xu Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease J Mol Neurosci 51 2 2013 539 549
103. S.Y. Lim, M. Hodaie, M. Fallis, Y.Y. Poon, F. Mazzella, and E. Moro Gamma knife thalamotomy for disabling tremor: A blinded evaluation Arch Neurol 67 5 2010 584 588
104. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 5111 1993 1130 1132
105. D. Lodge, A. Bond, M.J. O'Neill, C.A. Hicks, and M.G. Jones Stereoselective effects-of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies Neuropharmacology 35 12 1996 1681 1688
106. M. Lund-Johansen, K. Hugdahl, and K. Wester Cognitive function in patients with Parkinson's disease undergoing stereotaxic thalamotomy J Neurol Neurosurg Psychiatry 60 5 1996 564 571
107. J. Luo, M.G. Kaplitt, H.L. Fitzsimons, D.S. Zuzga, Y. Liu, and M.L. Oshinsky Subthalamic GAD gene therapy in a Parkinson's disease rat model Science 298 5592 2002 425 429
108. K.E. Lyons, and R. Pahwa The impact and management of nonmotor symptoms of Parkinson's disease Am J Manag Care 17 Suppl. 12 2011 S308 S314
109. C. Malagelada, Z.H. Jin, and L.A. Greene RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting akt phosphorylation/activation J Neurosci 28 53 2008 14363 14371
110. C. Malagelada, Z.H. Jin, V. Jackson-Lewis, S. Przedborski, and L.A. Greene Rapamycin protects against neuron death in in vitro and in vivo models of parkinson's disease J Neurosci 30 3 2010 1166 1175
111. C. Malagelada, E.J. Ryu, S.C. Biswas, V. Jackson-Lewis, and L.A. Greene RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation J Neurosci 26 39 2006 9996 10005
112. A.C. Maroney, J.P. Finn, D. Bozyczko-Coyne, T.M. O'Kane, N.T. Neff, and A.M. Tolkovsky CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults J Neurochem 73 5 1999 1901 1912
113. A.C. Maroney, J.P. Finn, T.J. Connors, J.T. Durkin, T. Angeles, and G. Gessner Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family J Biol Chem 276 27 2001 25302 25308
114. E. Martin, D. Jeanmonod, A. Morel, E. Zadicario, and B. Werner High-intensity focused ultrasound for noninvasive functional neurosurgery Ann Neurol 66 6 2009 858 861
115. M. Martínez-Banaclocha, N. Martínez, A.I. Hernández, and M.L. Ferrándiz Hypothesis: Can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci 64 15 1999 1253 1257
116. M. Martínez-Banaclocha N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice. Implications for treatment of Parkinson's disease Brain Res 859 2000 173 175
117. M. Martínez-Banaclocha N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? Med Hypotheses 79 2012 8 12
118. T.J. McCown, X. Xiao, J. Li, G.R. Breese, and R.J. Samulski Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector Brain Res 713 1-2 1996 99 107
119. K.S. McNaught Proteolytic dysfunction in neurodegenerative disorders Int Rev Neurobiol 62 2004 95 119
120. K.S. McNaught, and C.W. Olanow Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease Neurobiol Aging 27 4 2006 530 545
121. R. Mehanna, and J. Jankovic Respiratory problems in neurologic movement disorders Parkinsonism Relat Disord 16 10 2010 628 638
122. Merck Press Release Merck provides update on phase III clinical program for preladenant, the company's investigational Parkinson's disease medicine Available at http://www.mercknewsroom.com/press-release/research-and-development-news/merck-provides-update-phase-iii-clinical-program-prelade 2013, May 23
123. M. Merello, S. Starkstein, M.I. Nouzeilles, G. Kuzis, and R. Leiguarda Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation J Neurol Neurosurg Psychiatry 71 5 2001 611 614
124. D. Merims, I. Ziv, Y. Sherki, R. Djaldetti, and E. Melamed The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. potential therapeutic approaches Neurol Neurochir Pol 35 Suppl. 3 2001 65 68
125. A. Merola, M. Zibetti, S. Angrisano, L. Rizzi, M. Lanotte, and L. Lopiano Comparison of subthalamic nucleus deep brain stimulation and duodopa in the treatment of advanced Parkinson's disease Mov Disord 26 4 2011 664 670
126. A. Michotte Recent developments in the neuropathological diagnosis of Parkinson's disease and parkinsonism Acta Neurol Belg 103 3 2003 155 158
127. T. Muller, T. Buttner, A.F. Gholipour, and W. Kuhn Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with parkinson's disease Neurosci Lett 341 3 2003 201 204
128. C. Murakata, M. Kaneko, G. Gessner, T.S. Angeles, M.A. Ator, and T.M. O'Kane Mixed lineage kinase activity of indolocarbazole analogues Bioorg Med Chem Lett 12 2 2002 147 150
129. T. Nagatsua, and M. Sawadab l-Dopa therapy for Parkinson's disease: Past, present, and future Parkinsonism Relat Disord 15 Suppl. 1 2009 S3 S8
130. M. Naoi, and W. Maruyama Cell death of dopamine neurons in aging and Parkinson's disease Mech Ageing Dev 111 2-3 1999 175 188
131. D. Ngoga, R. Mitchell, J. Kausar, J. Hodson, A. Harries, and H. Pall Deep brain stimulation improves survival in severe Parkinson's disease J Neurol Neurosurg Psychiatry 85 1 2014 17 22
132. S.R. Nijhawan, S.J. Banks, T.Z. Aziz, I. Panourias, R. Gregory, and J. Yianni Changes in cognition and health-related quality of life with unilateral thalamotomy for parkinsonian tremor J Clin Neurosci 16 1 2009 44 50
133. K. Nishimura, and J. Takahashi Therapeutic application of stem cell technology toward the treatment of Parkinson's disease Biol Pharm Bull 36 2 2013 171 175
134. A.C. Nobrega, B. Rodrigues, and A. Melo Is silent aspiration a risk factor for respiratory infection in Parkinson's disease patients? Parkinsonism Relat Disord 14 8 2008 646 648
135. I. Nunes, L.T. Tovmasian, R.M. Silva, R.E. Burke, and S.P. Goff Pitx3 is required for development of substantia nigra dopaminergic neurons Proc Natl Acad Sci U S A 100 7 2003 4245 4250
136. J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, and E.R. Laws Jr. Study Group. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 1 2003 69 73
137. D. Nyholm, R. Jansson, T. Willows, and I.N. Remahl Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements Neurology 65 9 2005 1506 1507
138. J.A. Obeso, M.C. Rodriguez-Oroz, P. Chana, G. Lera, M. Rodriguez, and C.W. Olanow The evolution and origin of motor complications in Parkinson's disease Neurology 55 11 Suppl. 4 2000 S13 S20 (discussion S21-3)
139. V.J. Odekerken, T. van Laar, M.J. Staal, A. Mosch, C.F. Hoffmann, and P.C. Nijssen Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): A randomised controlled trial Lancet Neurol 12 1 2013 37 44
140. D. Offen, I. Ziv, H. Sternin, E. Melamed, and A. Hochman Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease Exp Neurol 141 1 1996 32 39
141. C. Ohye, Y. Higuchi, T. Shibazaki, T. Hashimoto, T. Koyama, and T. Hirai Gamma knife thalamotomy for Parkinson disease and essential tremor: A prospective multicenter study Neurosurgery 70 3 2012 526 535
142. M.S. Okun Deep-brain stimulation for Parkinson's disease N Engl J Med 367 16 2012 1529 1538
143. M.S. Okun, N.P. Stover, T. Subramanian, M. Gearing, B.H. Wainer, and C.A. Holder Complications of gamma knife surgery for Parkinson disease Arch Neurol 58 12 2001 1995 2002
144. M.S. Okun, and J.L. Vitek Lesion therapy for Parkinson's disease and other movement disorders: Update and controversies Mov Disord 19 4 2004 375 389
145. C.W. Olanow, C.G. Goetz, J.H. Kordower, A.J. Stoessl, V. Sossi, and M.F. Brin A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease Ann Neurol 54 3 2003 403 414
146. C.W. Olanow, P. Jenner, and D. Brooks Dopamine agonists and neuroprotection in Parkinson's disease Ann Neurol 44 3 Suppl. 1 1998 S167 S174
147. C.W. Olanow, and K.S. McNaught Ubiquitin-proteasome system and Parkinson's disease Mov Disord 21 11 2006 1806 1823
148. S. Ozawa, H. Kamiya, and K. Tsuzuki Glutamate receptors in the mammalian central nervous system Prog Neurobiol 54 1998 581 618
149. R. Pahwa, and K.E. Lyons Early diagnosis of Parkinson's disease: Recommendations from diagnostic clinical guidelines Am J Manag Care 16 Suppl 2010 S94 S99 (Implications:S94-9.)
150. C. Paisan-Ruiz, S. Jain, E.W. Evans, W.P. Gilks, J. Simón, and M. van der Brug Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 4 2004 595 600
151. S. Palfi, J.M. Gurruchaga, G.S. Ralph, H. Lepetit, S. Lavisse, and P.C. Buttery Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: A dose escalation, open-label, phase 1/2 trial Lancet 383 9923 2014 1138 1146
152. S.E. Palhagen, N. Dizdar, T. Hauge, B. Holmberg, R. Jansson, and J. Linder Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease Acta Neurol Scand 126 6 2012 e29 e33
153. S.M. Papa, and T.N. Chase Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys Ann Neurol 39 5 1996 574 578
154. C. Pardin, I. Roy, W.D. Lubell, and J.W. Keillor Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase Chem Biol Drug Des 72 3 2008 189 196
155. W.D. Parker Jr., S.J. Boyson, and J.K. Parks Abnormalities of the electron transport chain in idiopathic Parkinson's disease Ann Neurol 26 6 1989 719 723
156. Parkinson Study Group The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD Neurology 62 2 2004 330 332
157. Parkinson Study Group PRECEPT Investigators Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease Neurology 69 15 2007 1480 1490
158. N.K. Patel, M. Bunnage, P. Plaha, C.N. Svendsen, P. Heywood, and S.S. Gill Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study Ann Neurol 57 2 2005 298 302
159. J.B. Penney Jr., and A.B. Young Striatal inhomogeneities and basal ganglia function Mov Disord 1 1 1986 3 15
160. P. Piccini, and D.J. Brooks New developments of brain imaging for Parkinson's disease and related disorders Mov Disord 21 12 2006 2035 2041
161. P. Piccini, and A. Whone Functional brain imaging in the differential diagnosis of Parkinson's disease Lancet Neurol 3 5 2004 284 290
162. A. Pinna Adenosine A2A receptor antagonists in Parkinson's disease: Progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued CNS Drugs 28 5 2014 455 475
163. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 5321 1997 2045 2047
164. S. Przedborski, and V. Jackson-Lewis Mechanisms of MPTP toxicity Mov Disord 13 Suppl. 1 1998 35 38
165. R. Quelhas Psychiatric care in Parkinson's disease J Psychiatr Pract 19 2 2013 118 141
166. S.S. Rao, L.A. Hofmann, and A. Shakil Parkinson's disease: Diagnosis and treatment Am Fam Physician 74 12 2006 2046 2054
167. M. Récasens, J. Guiramand, R. Aimar, A. Abdulkarim, and G. Barbanel Metabotropic glutamate receptors as drug targets Curr Drug Targets 8 5 2007 651 681
168. Z. Ren, and Y. Zhang Cells therapy for Parkinson's disease - so close and so far away Sci China C Life Sci 52 7 2009 610 614
169. H.J. Rideout, P. Dietrich, M. Savalle, W.T. Dauer, and L. Stefanis Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons J Neurochem 84 4 2003 803 813
170. R.L. Rodnitzky The use of sinemet CR in the management of mild to moderate Parkinson's disease Neurology 42 1 Suppl. 1 1992 44 50 (discussion 57-60)
171. R. Roshan, T. Ghosh, V. Scaria, and B. Pillai MicroRNAs: Novel therapeutic targets in neurodegenerative diseases Drug Discov Today 14 23-24 2009 1123 1129
172. 2A receptors in brain Neurology 61 2003 12 18
173. H.M. Ruottinen, and U.K. Rinne COMT inhibition in the treatment of Parkinson's disease J Neurol 245 11 Suppl. 3 1998 P25 P34
174. M.S. Saporito, E.M. Brown, M.S. Miller, and S. Carswell CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo J Pharmacol Exp Ther 288 2 1999 421 427
175. M.S. Saporito, B.A. Thomas, and R.W. Scott MPTP activates c-jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo J Neurochem 75 3 2000 1200 1208
176. A.H. Schapira Safinamide in the treatment of Parkinson's disease Expert Opin Pharmacother 11 13 2010 2261 2268
177. A.H. Schapira Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: A review of symptomatic and potential disease-modifying effects CNS Drugs 25 12 2011 1061 1071
178. A.H. Schapira, F. Stocchi, R. Borgohain, M. Onofrj, M. Bhatt, and P. Lorenzana Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease Eur J Neurol 20 2 2013 271 280
179. W.M. Schuepbach, J. Rau, K. Knudsen, J. Volkmann, P. Krack, and L. Timmermann Neurostimulation for Parkinson's disease with early motor complications N Engl J Med 368 7 2013 610 622
180. H. Shichinohe, S. Kuroda, H. Yasuda, T. Ishikawa, M. Iwai, and M. Horiuchi Neuroprotective effects of the free radical scavenger edaravone (MCI-186) in mice permanent focal brain ischemia Brain Res 1029 2 2004 200 206
181. C.W. Shults, D. Oakes, K. Kieburtz, M.F. Beal, R. Haas, and S. Plumb Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline Arch Neurol 59 10 2002 1541 1550
182. K.A. Sillay, P.S. Larson, and P.A. Starr Deep brain stimulator hardware-related infections: Incidence and management in a large series Neurosurgery 62 2 2008 360 366 (discussion 366-7)
183. D.E. Silver Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo) Expert Rev Neurother 4 4 2004 589 599
184. A. Sofer, K. Lei, C.M. Johannessen, and L.W. Ellisen Regulation of mTOR and cell growth in response to energy stress by REDD1 Mol Cell Biol 25 14 2005 5834 5845
185. E.C. Stack, J.L. Ferro, J. Kim, S.J. Del Signore, S. Goodrich, and S. Matson Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease Biochim Biophys Acta 1782 3 2008 151 162
186. F. Stocchi, O. Rascol, A. Destee, N. Hattori, R.A. Hauser, and A.E. Lang AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study Mov Disord 28 13 2013 1838 1846
187. F. Stocchi, L. Vacca, S. Ruggieri, and C.W. Olanow Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study Arch Neurol 62 6 2005 905 910
188. A.M. Strutt, E.C. Lai, J. Jankovic, F. Atassi, E.M. Soety, and H.S. Levin Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease Surg Neurol 71 5 2009 551 558
189. F.X. Sureda, F. Junyent, E. Verdaguer, C. Auladell, C. Pelegri, and J. Vilaplana Antiapoptotic drugs: A therapautic strategy for the prevention of neurodegenerative diseases Curr Pharm Des 17 3 2011 230 245
190. C.M. Tanner, J.P. Hubble, and P. Chan Epidemiology and genetics of Parkinson's disease R.L. Watts, W.L. Koller, Movement Disorders: Neurological Principles and Practice 1997 McGraw Hill New York 137 152
191. N.A. Tatton, A. Maclean-Fraser, W.G. Tatton, D.P. Perl, and C.W. Olanow A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease Ann Neurol 44 3 Suppl. 1 1998 S142 S148
192. V.L. Tawfik, S.Y. Chang, F.L. Hitti, D.W. Roberts, J.C. Leiter, and S. Jovanovic Deep brain stimulation results in local glutamate and adenosine release: Investigation into the role of astrocytes Neurosurgery 67 2 2010 367 375
193. Y. Temel Limbic effects of high-frequency stimulation of the subthalamic nucleus Vitam Horm 82 2010 47 63
194. H. Teramoto, O.C. Coso, H. Miyata, T. Igishi, T. Miki, and J.S. Gutkind Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway J Biol Chem 271 1996 27225 27228
195. J. Tereshchenko, A. Maddalena, M. Bähr, and S. Kügler Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease Neurobiol Dis 65 2014 35 42
196. The Parkinson Study Group QE3 Investigators A randomized clinical trial of high-dosage Coenzyme Q10 in early Parkinson disease: No evidence of benefit JAMA Neurol 71 5 2014 543 552
197. A. Thomas, D. Iacono, A.L. Luciano, K. Armellino, A. Di Iorio, and M. Onofrj Duration of amantadine benefit on dyskinesia of severe Parkinson's disease J Neurol Neurosurg Psychiatry 75 1 2004 141 143
198. R. Tintner, and J. Jankovic Dopamine agonists in Parkinson's disease Expert Opin Investig Drugs 12 11 2003 1803 1820
199. F. Tison, F. Durif, and Christophe J. Safety Tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) Parkinson's disease (PD) patients with levodopa-induced dyskinesia; Poster presented at: 65th American Academy of Neurology Annual Meeting; March 16-23, 2013; San Diego, CA, USA 2013
200. E. Tolosa, G. Wenning, and W. Poewe The diagnosis of Parkinson's disease Lancet Neurol 5 1 2006 75 86
201. C. Turner, and A.H. Schapira Mitochondrial dysfunction in neurodegenerative disorders and ageing Adv Exp Med Biol 487 2001 229 251
202. I. Valalik, S. Sagi, D. Solymosi, and J. Julow CT-guided unilateral thalamotomy with macroelectrode mapping for the treatment of Parkinson's disease Acta Neurochir (Wien) 143 10 2001 1019 1030
203. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, and S. Gispert Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 5674 2004 1158 1160
204. V. Vedam-Mai, E.Y. van Battum, W. Kamphuis, M.G. Feenstra, D. Denys, and B.A. Reynolds Deep brain stimulation and the role of astrocytes Mol Psychiatry 17 2 2012 124 131 (115)
205. L. Verhagen, L. Metman, P. Del Dotto, P. van den Munckhof, J. Fang, and M.M. Mouradian Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease Neurology 50 5 1998 1323 1326
206. I. Vermes, E.N. Steur, G.F. Jirikowski, and C. Haanen Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis Mov Disord 19 10 2004 1252 1254
207. 2A Receptor Antagonist Programme for Parkinson's Disease Continues with Next Generation Compound 2010, July 16 2010, July 16
208. J. Voges, Y. Waerzeggers, M. Maarouf, R. Lehrke, A. Koulousakis, and D. Lenartz Deep-brain stimulation: Long-term analysis of complications caused by hardware and surgery - experiences from a single centre J Neurol Neurosurg Psychiatry 77 7 2006 868 872
209. Z. Wang, M.H. Malone, M.J. Thomenius, F. Zhong, F. Xu, and C.W. Distelhorst Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals J Biol Chem 278 29 2003 27053 27058
210. G. Wang, J.M. van der Walt, G. Mayhew, Y.J. Li, S. Züchner, and W.K. Scott Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein Am J Hum Genet 82 2 2008 283 289
211. T. Wichmann, M.R. DeLong, J. Guridi, and J.A. Obeso Milestones in research on the pathophysiology of Parkinson's disease Mov Disord 26 6 2011 1032 1041
212. L.D. Wood, J.J. Neumiller, S.M. Setter, and E.K. Dobbins Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease Am J Geriatr Pharmacother 8 4 2010 294 315
213. W.J. Yuan, T. Yasuhara, T. Shingo, K. Muraoka, T. Agari, and M. Kameda Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons BMC Neurosci 9 2008 (75-2202-9-75)
214. L. Zrinzo, T. Foltynie, P. Limousin, and M.I. Hariz Reducing hemorrhagic complications in functional neurosurgery: A large case series and systematic literature review J Neurosurg 116 1 2012 84 94
215. A.D. Zurn, H.R. Widmer, and P. Aebischer Sustained delivery of GDNF: Towards a treatment for Parkinson's disease Brain Res Rev 36 2-3 2001 222 229